Home | Welcome to Contract Pharma   
Last Updated Friday, May 29 2015


Financial Report: Emergent BioSolutions

Published August 8, 2014
Emergent BioSolutions

2Q Revenues: $110.3 million (+34%)

2Q Earnings: $5.0 million (+51%)

YTD Revenues: $164.2 million (+31%)

YTD Loss: $15.2 million (earnings were $2.4 million YTD13)

Comments: This was the first full quarter of combined operations with Cangene.Product sales were $78.3 million, up 19%. Revenue from BioThrax was $67.5 million in the quarter, up 3%. Contract manufacturing revenue was $9.2 million in the quarter. R&D expenses were $37.4 million, up 23% primarily due to higher contract service costs, and includes increased technology and development expenses in both the Biodefense and Biosciences divisions.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On